Citrus bergamot is a small yellow citrus fruit grown almost exclusively on the Calabrian coast of southern Italy. The juice and pulp contain a rare combination of flavonoids that lower LDL cholesterol and triglycerides, raise HDL, and improve insulin sensitivity. It's one of the most researched natural interventions for dyslipidemia that isn't a drug.
Generally used as a first line defense and OTC alternative to bring cholesterol numbers down without going on a statin, but also works along side statins. It's also relevant for anyone with metabolic syndrome, fatty liver (NAFLD), insulin resistance, or anyone exogenous hormones that have pushed their lipids in the wrong direction.
There are two very different bergamot products on the market, and confusing them is the single most common mistake. Bergamot essential oil (cold-pressed from the peel) is the stuff in perfume and Earl Grey tea. It contains furocoumarins like bergapten and bergamottin that are phototoxic on the skin and can interact with drugs. Don't take it orally for cholesterol. The bergamot polyphenolic fraction (BPF), a standardized extract made from the juice and pulp, is what the clinical trials used. When this page talks about bergamot supplements, it means BPF or a comparable standardized flavonoid extract. Essential oil is a separate product with separate uses and separate risks.
deep dive
The active compounds are a specific set of flavonoids: neoeriocitrin, neohesperidin, naringin, and two molecules that are fairly unique to bergamot, brutieridin and melitidin. Italian researchers showed that brutieridin and melitidin contain a 3-hydroxy-3-methylglutaryl (HMG) moiety, the same chemical group that defines statin drugs. This moiety lets them slot into the active site of HMG-CoA reductase, the enzyme that controls cholesterol synthesis in the liver. That's why bergamot is sometimes described as having "statin-like" activity, though it's a much weaker inhibition than a prescription statin, and the lipid-lowering effect clearly comes from more than just that one pathway.
The other main mechanism is AMPK activation. Bergamot flavonoids activate AMP-activated protein kinase, which is the same target hit by metformin. Mechanistic reviews describe how AMPK activation increases fatty acid oxidation, suppresses SREBP-1 and HNF4-driven VLDL production, improves GLUT4-mediated glucose uptake in muscle, and dials down hepatic lipogenesis. This is why bergamot consistently lowers triglycerides and fasting glucose, not just LDL. Alongside these, bergamot inhibits pancreatic cholesterol ester hydrolase (reducing dietary cholesterol absorption), upregulates the LDL receptor on hepatocytes (pulling more LDL out of circulation), reduces oxidized LDL, and improves endothelial nitric oxide signalling. It's a multi-target compound, not a single-pathway one.
The clinical evidence. The landmark trial is Mollace et al. 2011, a randomized placebo-controlled study in 237 patients with hyperlipidemia or metabolic syndrome. After 30 days of 500 or 1000 mg/day of BPF, total cholesterol dropped roughly 20-30%, LDL roughly 24-39%, triglycerides roughly 30-41%, and HDL increased 22-39%. In a subgroup with metabolic syndrome, fasting glucose also fell around 22%. A separate arm of the same study gave 1500 mg/day BPF to 32 statin-intolerant patients and achieved a 25% drop in total cholesterol and a 27.6% drop in LDL without the statin side effects returning. A 2013 trial then showed that combining BPF with 10 mg rosuvastatin produced greater LDL reduction (around 52% vs placebo) than either agent alone, suggesting real synergy rather than redundancy.
A 2019 systematic review of 12 human studies found 75% of trials reported significant reductions in total cholesterol, LDL, and triglycerides, with ranges of 12-31% for total cholesterol, 7-41% for LDL, and 11-39% for triglycerides. The wide ranges reflect differences in extract standardization, baseline lipid levels, and patient populations, not inconsistency in direction of effect. A 2022 meta-analysis of 14 RCTs pooled the data and found mean reductions of around 63 mg/dL in total cholesterol, 55 mg/dL in LDL, 75 mg/dL in triglycerides, and an increase of around 6 mg/dL in HDL. The International Lipid Expert Panel gave bergamot a Class IIa recommendation with Level B evidence for dyslipidemia, which is the strongest recommendation any nutraceutical currently holds for lipid-lowering.
Beyond lipids. A 6-month prospective study (Toth 2015) using 150 mg/day of standardized bergamot flavonoids showed reductions in small dense LDL particles (the most atherogenic LDL subclass) and improvements in carotid intima-media thickness, suggesting the lipid changes translate into earlier-stage atherosclerotic benefit. For fatty liver, a 2020 RCT in NAFLD patients combining BPF with artichoke extract reduced total cholesterol by 23%, LDL by 28%, triglycerides by 30%, and significantly improved liver fat on imaging. Animal work consistently shows reduced hepatic steatosis via activation of lipophagy in the liver.
Women-specific evidence. Most of the lipid trials enrolled both sexes and didn't publish sex-stratified results, which is a real limitation. What does exist is directly relevant: Wolkodoff et al. studied postmenopausal women who were already exercising and found that bergamot supplementation improved VO2 max by 12% and Utian Quality of Life scores by 15% versus placebo in exercise-matched controls. This matters because menopause is when most women's lipid profiles deteriorate (falling estradiol means less eNOS, worse endothelial function, higher LDL, and rising cardiovascular risk), and bergamot addresses several of those mechanisms at once. A prospective observational study in postmenopausal breast cancer patients on aromatase inhibitors, who develop drug-induced dyslipidemia as a near-universal side effect, showed significant improvements in total cholesterol, LDL, HDL, and triglycerides on bergamot. Women on hormonal contraception, HRT, or dealing with PCOS-related dyslipidemia and insulin resistance fit the same general mechanistic profile as the populations studied, and responses are expected to track with those of men at equivalent doses.
Limitations of the evidence. Most of the positive trials were conducted by the same small group of Italian research centres using proprietary extracts (BPF, Bergavit, Bergamet, Endoberg), often with industry funding. A recent 4-month RCT using Bergavit40 at 375 mg/day found no significant LDL reduction versus placebo, which is a useful counter-data point and highlights that not every standardized extract at every dose works. Extract quality, flavonoid content, and the presence of brutieridin and melitidin matter enormously. The human pharmacokinetics of bergamot flavonoids are also still poorly characterized, which makes it hard to know exactly how much active compound is reaching the liver from a given capsule. None of this invalidates the overall signal, it's just worth being aware that "bergamot 500 mg" on one label can be chemically quite different from "bergamot 500 mg" on another.
Dosage:
- Starting and standard dose: 500 my taken once or twice a day of standardized BPF (bergamot polyphenolic fraction), taken 15-30 minutes before the main meal of the day. Most clinical benefit is seen in this range
- Higher-end dose for poor response or statin-intolerant patients: 1500 mg/day, split into two doses (before lunch and before dinner). This is the dose used in the Mollace 2011 statin-intolerant arm
- Phytosomal / lecithin-formulated bergamot: 300 mg/day (typically 150 mg twice daily). The phytosomal form has higher bioavailability, so the effective dose is lower. If the label says phytosome, phytosomal, or lecithin-formulated, don't just match the milligrams of standard BPF
- Standardized flavonoid extracts (e.g. Bergavit40): 150 mg/day of flavonoids (which typically corresponds to around 500-550 mg of extract), taken with the evening meal
- Timing: Take before meals rather than after. The cholesterol-ester-hydrolase inhibition and the interference with dietary cholesterol absorption both require bergamot to be present in the gut when food arrives
- Duration to see results: Lipid changes are typically visible on bloodwork at 4-8 weeks. Maximum effect usually by 3-6 months. Bergamot is a long-term intervention, not an acute one
- What to look for on a label: standardization to flavonoids (usually 38-47% total flavonoids), and ideally an explicit statement of brutieridin and melitidin content. Extracts without these two compounds are probably just naringin and are unlikely to work as well. "Bergamot extract" with no standardization on the label is a gamble
- Stacking: pairs well with berberine (complementary AMPK activation plus glucose effects), omega-3s (triglyceride reduction through a different mechanism), and red yeast rice or a low-dose statin for additive LDL lowering. If stacking with a statin, check liver enzymes at 6-8 weeks since both act on the liver, though no meaningful hepatotoxicity signal has been reported for the combination
Here's what you can expect:
If your baseline LDL or triglycerides are elevated, you should see measurable movement on a lipid panel at 4-8 weeks, with the full effect usually landing by 3-6 months. Expect roughly 15-30% reductions in total cholesterol and LDL, 15-40% reductions in triglycerides, and a 5-40% increase in HDL, depending on how high your baseline was and which extract you're using. Higher baselines see bigger absolute changes. If your baseline lipids are already excellent, the effect will be small and probably not worth the cost.
On glucose, if you have insulin resistance or metabolic syndrome, expect a modest drop in fasting glucose (5-20%) and improvement in HOMA-IR over the same 3-6 month window. Subjectively, most people don't feel anything on bergamot the way they'd feel caffeine or creatine. It's a quiet intervention that shows up on bloodwork, not in the mirror. Some users report slightly better exercise tolerance and recovery, which lines up with the endothelial and nitric oxide data.
Side effects & risks:
- Generally very well tolerated. Across the major RCTs, adverse event rates were not significantly different from placebo, and most trials reported no dropouts due to side effects
- Mild heartburn or gastric reflux is the most commonly reported side effect, seen in roughly 3-6% of users at 500-1000 mg, slightly more at 1500 mg. Usually resolves with taking it alongside a small amount of food instead of fully fasted
- Loose stools or mild GI upset can occur in the first 1-2 weeks, typically resolves on its own
- Hypoglycemia risk is low if you're diabetic and on glucose-lowering medication (metformin, sulfonylureas, insulin). Bergamot's AMPK activation can add to the effect of these drugs. Monitor blood sugar closely in the first month if you're on diabetic medication
- Potential additive effect with statins. This can be a feature (better LDL control) or a problem (theoretically higher risk of muscle symptoms). Human trials combining the two for up to 30 days didn't show increased myopathy, but long-term combination hasn't been formally studied. If you develop muscle aches on a bergamot-statin combo, stop the bergamot first and see if symptoms resolve
- Drug interactions via CYP3A4. This is the most important caveat and is widely misunderstood. The bergamot polyphenolic fraction (juice/pulp extract) contains minimal furocoumarins, so CYP3A4 interactions are much smaller than with grapefruit juice. The bergamot essential oil and some whole-fruit preparations contain bergamottin and 6',7'-dihydroxybergamottin, which are the same suicide inhibitors of intestinal CYP3A4 that cause the grapefruit effect. If your supplement specifies BPF or is standardized to flavonoid content, the CYP3A4 risk is low. If it's a whole-fruit powder or contains essential oil, assume grapefruit-level interactions and avoid combining with CYP3A4-metabolized drugs (many statins, calcium channel blockers, immunosuppressants, some benzodiazepines, certain antiarrhythmics). When in doubt, treat bergamot like grapefruit
- Bergamot essential oil is phototoxic when applied to skin due to bergapten. This is a topical/aromatherapy issue, not an oral supplement issue, but it's worth flagging because the two products get conflated. Don't take bergamot essential oil orally for cholesterol
- Pregnancy and breastfeeding: no adequate safety data. Avoid
- Children and adolescents: no adequate safety data. Avoid unless under specialist supervision
- Known allergy to citrus fruits: avoid
- Consult your doctor before starting if you're on any lipid-lowering drug, diabetic medication, immunosuppressant, or anticoagulant
Blood markers
Full lipid panel (total cholesterol, LDL, HDL, triglycerides, non-HDL), at baseline, 8 weeks, and 3-6 months. This is the primary reason you're taking bergamot, track it. Non-HDL and ApoB are more informative than LDL alone if you can get them
ApoB, at baseline and 3 months if available. A better predictor of cardiovascular risk than LDL-C and responsive to bergamot
Fasting glucose and HbA1c, at baseline and 3 months, especially if you have insulin resistance, metabolic syndrome, or are on a cycle. Also essential if you're taking diabetic medication, to catch any additive hypoglycemic effect
Liver enzymes (ALT, AST, GGT), at baseline and 3 months. Bergamot is safe on the liver and often improves these markers in people with fatty liver, but anyone combining it with a statin, orals, or other hepatotoxic compounds should monitor
hs-CRP, optional but useful if you're tracking cardiovascular risk comprehensively. Bergamot consistently lowers it in trials
For most people, a standard lipid panel plus fasting glucose at baseline and 3 months is enough.
Bergamot extracts sit outside standard drug approval frameworks and are classified as food supplements in most jurisdictions.
Made with Bullet